1967-88-0

Basic information

• Product Name: 6-amino-2,3,4-trimethoxybenzoic acid
• Synonyms: 6-amino-2,3,4-trimethoxybenzoic acid
• CAS NO: 1967-88-0
• Molecular Weight: 227.217
• Mol File: 1967-88-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 6-amino-2,3,4-trimethoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-amino-2,3,4-trimethoxybenzoic acid(1967-88-0)
• EPA Substance Registry System: 6-amino-2,3,4-trimethoxybenzoic acid(1967-88-0)

Safety Data

• Hazardous Substances Data: 1967-88-0(Hazardous Substances Data)

Upstream product

• 573-11-5 2,3,4-Trimethoxy-benzoic acid 
• 102439-00-9 3,4,5-trimethoxyaniline hydrochloride 
• 784-06-5 4,5,6-Trimethoxyisatin 
• 24313-88-0 3,4,5-Trimethoxyaniline 
• 61948-84-3 2,3,4-trimethoxy-6-nitrobenzoic acid 

Downstream Products

• 13082-16-1 1,2,3-Trimethoxy-N-methylacridon 
• 1968-72-5 methyl 6-amino-2,3,4-trimethoxy benzoate 
• 124346-74-3 5,6,7-trimethoxy-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 

Relevant articles and documents

QUINAZOLINE COMPOUNDS

Disclosed are compounds having the formula: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, and methods of making and using the same.

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor

4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (32, PD 153035) is a very potent inhibitor (IC50 0.025 nM) of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), binding competitively at the ATP site. Structure-activity relationships for close analogues of 32 are very steep. Some derivatives have IC50s up to 80-fold better than predicted from simple additive binding energy arguments, yet analogues possessing combinations of similar phenyl and quinazoline substituents do not show this 'supra-additive' effect. Because some substituents which are mildly deactivating by themselves can be strongly activating when used in the correct combinations, it is proposed that certain substituted analogues possess the ability to induce a change in the conformation of the receptor when they bind. There is some bulk tolerance for substitution in the 6- and 7-positions of the quinazoline, so that 32 is not the optimal inhibitor for the induced conformation. The diethoxy derivative 56 [4-(3-bromoanilino)- 6,7-diethoxy-quinazoline] shows an IC50 of 0.006 nM, making it the most potent inhibitor of the tyrosine kinase activity of the EGFR yet reported.

2-(Piperazinyl)-4-pyrimioinamines

Herein is disclosed 2-(1-piperazinyl)-4-pyrimidinamine derivatives, acid addition salts thereof, processes for their preparation, methods of using the derivatives and pharmaceutical compositions of the derivatives. The derivatives are distinguished most readily by having novel substituents at position 4 of the piperazinyl radical, the substituents being selected from the group consisting of optionally substituted 2-cycloheptimidazolyl, 1,4,5,6,7,8-hexahydrocycloheptimidazol-2-yl, 2-benzoxazolyl, benzthiazol-2-yl, 1H-2-benzimidazolyl and 1-oxo-2,4,6-cycloheptarien-2-yl. The derivatives are useful for treating hypertension in a mammal.